Research programme: small molecules - BioCryst
Latest Information Update: 22 May 2014
At a glance
- Originator BioCryst Pharmaceuticals
- Class Small molecules
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase Unknown Unspecified
Most Recent Events
- 01 Mar 2014 Investigation in Undefined indication in USA (unspecified route)